Taysha Gene Therapies (TSHA) Other Operating Expenses (2020 - 2025)

Taysha Gene Therapies has disclosed Other Operating Expenses across 6 years of filings, most recently posting $83.4 million for Q4 2025.

• Other Operating Expenses for Q4 2025 came in at $83.4 million, up 28.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $83.4 million (up 19.42% YoY), and the FY2025 annual result was $83.4 million, up 19.42% from the prior year.
• Other Operating Expenses came in at $83.4 million for Q4 2025 at Taysha Gene Therapies, up from $65.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $128.9 million in Q4 2021 to a low of $616000.0 in Q3 2023.
• The 5-year median for Other Operating Expenses is $37.2 million (2022), against an average of $50.7 million.
• Across the five-year window, Other Operating Expenses slumped 71.75% in 2022 and jumped 685.39% in 2024, its largest moves.
• Taysha Gene Therapies' Other Operating Expenses stood at $128.9 million in 2021, then plunged by 71.75% to $36.4 million in 2022, then jumped by 122.88% to $81.2 million in 2023, then fell by 19.92% to $65.0 million in 2024, then rose by 28.31% to $83.4 million in 2025.
• The last three Other Operating Expenses figures came in at $83.4 million (Q4 2025), $65.0 million (Q4 2024), and $4.8 million (Q3 2024), per Business Quant data.